Imeik Technology DevelopmentLtd Past Earnings Performance
Past criteria checks 5/6
Imeik Technology DevelopmentLtd has been growing earnings at an average annual rate of 36.8%, while the Biotechs industry saw earnings growing at 5.4% annually. Revenues have been growing at an average rate of 32.8% per year. Imeik Technology DevelopmentLtd's return on equity is 28.3%, and it has net margins of 65.7%.
Key information
36.8%
Earnings growth rate
33.7%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 32.8% |
| Return on equity | 28.3% |
| Net Margin | 65.7% |
| Last Earnings Update | 30 Jun 2024 |
Revenue & Expenses Breakdown
How Imeik Technology DevelopmentLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 3,067 | 2,016 | 383 | 272 |
| 31 Mar 24 | 3,047 | 1,972 | 390 | 264 |
| 31 Dec 23 | 2,869 | 1,858 | 409 | 250 |
| 30 Sep 23 | 2,620 | 1,695 | 422 | 217 |
| 30 Jun 23 | 2,513 | 1,642 | 398 | 213 |
| 31 Mar 23 | 2,138 | 1,404 | 332 | 188 |
| 01 Jan 23 | 1,939 | 1,264 | 291 | 173 |
| 30 Sep 22 | 1,914 | 1,236 | 276 | 156 |
| 30 Jun 22 | 1,699 | 1,118 | 258 | 123 |
| 31 Mar 22 | 1,619 | 1,061 | 258 | 108 |
| 01 Jan 22 | 1,448 | 958 | 221 | 102 |
| 30 Sep 21 | 1,268 | 858 | 189 | 90 |
| 30 Jun 21 | 1,101 | 718 | 164 | 85 |
| 31 Mar 21 | 889 | 567 | 134 | 78 |
| 31 Dec 20 | 709 | 440 | 114 | 62 |
| 30 Sep 20 | 627 | 376 | 113 | 51 |
| 31 Dec 19 | 558 | 306 | 126 | 49 |
| 31 Dec 18 | 321 | 123 | 107 | 34 |
| 31 Dec 17 | 222 | 82 | 68 | 28 |
| 31 Dec 16 | 141 | 53 | 60 | 0 |
| 31 Dec 15 | 112 | 18 | 74 | 0 |
| 31 Dec 14 | 75 | 28 | 36 | 0 |
Quality Earnings: 300896 has high quality earnings.
Growing Profit Margin: 300896's current net profit margins (65.7%) are higher than last year (65.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300896's earnings have grown significantly by 36.8% per year over the past 5 years.
Accelerating Growth: 300896's earnings growth over the past year (22.8%) is below its 5-year average (36.8% per year).
Earnings vs Industry: 300896 earnings growth over the past year (22.8%) exceeded the Biotechs industry -0.3%.
Return on Equity
High ROE: 300896's Return on Equity (28.3%) is considered high.